Comparison of Biochemical Parameters Among DPP4 Inhibitor Users and Other Oral Hypoglycaemic Drug Users: a Cross-sectional Study from Anuradhapura, Sri Lanka

Overview

Journal J Health Popul Nutr

Publisher Biomed Central

Specialties Nutritional Sciences
Public Health

Date 2019 Jan 25

PMID 30674350

Citations 1

Authors

Devarajan Rathish

Channa Jayasumana

Suneth Agampodi

Affiliations

Soon will be listed here.

Abstract

Background: Higher efficacy of incretin-based therapies for type 2 diabetes mellitus has been reported from Asia. Pancreatitis and hepatitis have also been suspected to occur due to dipeptidyl peptidase-4 inhibitor (DPP4I) treatment. The present study aims at comparing selected biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users.

Methods: Patients were recruited from the State Pharmaceutical Corporation, Anuradhapura, Sri Lanka, for a comparative cross-sectional study. Two groups were involved: "DPP4I" user group (n = 63) and "other oral hypoglycaemic" user group (n = 126). Mann-Whitney U test was performed to find a significant difference (p < 0.05) in the distributions of HbA, pancreatic amylase, serum lipase, AST and ALT levels between the two groups.

Results: Contradicting to previous Asian studies, distribution of HbA (p = 0.569) between anti-diabetic regimes with and without DPP4 inhibitors showed no significant difference. Also, amylase (p = 0.171), AST (p = 0.238) and ALT (p = 0.347) failed to show significance. However, lipase was significantly (p = 0.012) high in the DPP4I group.

Conclusion: The study showed a significantly higher lipase level among the DPP4I users in comparison to other oral hypoglycaemic drug users, and possible reasons were discussed.

Citing Articles

Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.

Okada J, Yamada E, Niijima Y, Okada S, Yamada M J Health Popul Nutr. 2019; 38(1):33.

PMID: 31727181 PMC: 6854662. DOI: 10.1186/s41043-019-0197-x.

References

Giorda C, Nada E, Tartaglino B, Marafetti L, Gnavi R . A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014; 16(11):1041-7. DOI: 10.1111/dom.12297. View

Kim H, Shin J, Lee S, Kim E, Cho J, Son H . A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013; 15(10):810-6. DOI: 10.1089/dia.2013.0038. View

Liao K, Lin C, Lai S, Chen W . Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: A population-based case-control study in Taiwan. Eur J Intern Med. 2015; 27:76-9. DOI: 10.1016/j.ejim.2015.09.015. View

Chang C, Lin J, Chen S, Lai M, Chuang L, Chang Y . Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study. Medicine (Baltimore). 2016; 95(7):e2603. PMC: 4998601. DOI: 10.1097/MD.0000000000002603. View

Rathish D, Senavirathna I, Jayasumana C, Agampodi S, Siribaddana S . A low GLP-1 response among patients treated for acute organophosphate and carbamate poisoning: a comparative cross-sectional study from an agrarian region of Sri Lanka. Environ Sci Pollut Res Int. 2018; 26(3):2864-2872. DOI: 10.1007/s11356-018-3818-9. View

Ni Q, Yun L, Xu R, Shang D . Correlation between blood lipid levels and chronic pancreatitis: a retrospective case-control study of 48 cases. Medicine (Baltimore). 2014; 93(28):e331. PMC: 4603079. DOI: 10.1097/MD.0000000000000331. View

Scheen A . Pathophysiology of type 2 diabetes. Acta Clin Belg. 2004; 58(6):335-41. DOI: 10.1179/acb.2003.58.6.001. View

Morisky D, Green L, Levine D . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1):67-74. DOI: 10.1097/00005650-198601000-00007. View

Gifford R, Siribaddana S, Forbes S, Eddleston M . Endocrine-disrupting chemicals and the diabetes epidemic in countries in the WHO South-East Asia region. Lancet Diabetes Endocrinol. 2015; 3(12):925-7. DOI: 10.1016/S2213-8587(15)00423-4. View

10.

Seino Y, Fukushima M, Yabe D . GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2014; 1(1-2):8-23. PMC: 4020673. DOI: 10.1111/j.2040-1124.2010.00022.x. View

11.

Giorda C, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R . Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2014; 48(2):461-71. DOI: 10.1007/s12020-014-0386-8. View

12.

Thomsen R, Pedersen L, Moller N, Kahlert J, Beck-Nielsen H, Sorensen H . Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care. 2015; 38(6):1089-98. DOI: 10.2337/dc13-2983. View

13.

Rathish D, Bahini S, Sivakumar T, Thiranagama T, Abarajithan T, Wijerathne B . Drug utilization, prescription errors and potential drug-drug interactions: an experience in rural Sri Lanka. BMC Pharmacol Toxicol. 2016; 17(1):27. PMC: 4921016. DOI: 10.1186/s40360-016-0071-z. View

14.

Li L, Shen J, Bala M, Busse J, Ebrahim S, Vandvik P . Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014; 348:g2366. PMC: 3987051. DOI: 10.1136/bmj.g2366. View

15.

Jamaluddin J, Huri H, Vethakkan S . Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016; 17(8):867-81. DOI: 10.2217/pgs-2016-0010. View

16.

PERLEY M, KIPNIS D . Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967; 46(12):1954-62. PMC: 292948. DOI: 10.1172/JCI105685. View

17.

Lasram M, Dhouib I, Annabi A, El Fazaa S, Gharbi N . A review on the molecular mechanisms involved in insulin resistance induced by organophosphorus pesticides. Toxicology. 2014; 322:1-13. DOI: 10.1016/j.tox.2014.04.009. View

18.

Steinberg W, Nauck M, Zinman B, Daniels G, Bergenstal R, Mann J . LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas. 2014; 43(8):1223-31. PMC: 4206347. DOI: 10.1097/MPA.0000000000000229. View

19.

Rathish D, Agampodi S, Jayasumana M, Siribaddana S . From organophosphate poisoning to diabetes mellitus: The incretin effect. Med Hypotheses. 2016; 91:53-55. DOI: 10.1016/j.mehy.2016.04.002. View

20.

Wan J, He W, Zhu Y, Zhu Y, Zeng H, Liu P . Stratified analysis and clinical significance of elevated serum triglyceride levels in early acute pancreatitis: a retrospective study. Lipids Health Dis. 2017; 16(1):124. PMC: 5488442. DOI: 10.1186/s12944-017-0517-3. View